SCHEMBL6097539

SCHEMBL6097539

Cc1nc(N)c2nc(C)n(CCCNC(=O)C(C)C)c2c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
MTNR1A P48039 6/20 0.35
MTNR1B P49286 6/20 0.35
CYP2C19 P33261 3/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
BRD4 O60885 4/20 0.33
RECQL P46063 1/20 0.33
PIM1 P11309 1/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
CSNK2A3 Q8NEV1 1/20 0.33
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GAA P10253 1/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096758 0.93 MEN1 (0.42) KMT2AMEN1HTTMTNR1AMTNR1B
SCHEMBL6094589 0.87 DYRK1A (0.37) MTNR1AMTNR1BPIM1CSNK2A2CSNK2B
SCHEMBL4794572 0.87 MEN1 (0.35) KMT2AMEN1HTTCYP2C19CYP2C9
SCHEMBL6776898 0.86 EPHX1 (0.37) HTTBRD4PIM1CSNK2A2CSNK2B
SCHEMBL6094673 0.84 TLR7 (0.40) TLR7
SCHEMBL6775775 0.84 EPHX1 (0.37) KMT2ARECQLGAACYP3A4TLR7
SCHEMBL6773171 0.82 TSHR (0.38) KMT2AMEN1HTTMTNR1AMTNR1B
SCHEMBL6773502 0.82 TLR7 (0.37) KMT2ASMN1; SMN2TLR7
SCHEMBL3876239 0.81 TLR7 (0.55) MTNR1AMTNR1BTLR7
SCHEMBL4079869 0.80 TLR7 (0.33) KMT2AMEN1HTTMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186128-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-23 US claimed
EP-1451187-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-01 EP claimed
US-20030186949-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 US claimed
US-20030162806-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US claimed
WO-2003050118-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO claimed
US-6545016-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 US claimed
US-7098221-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-08-29 US disclosed
US-20050282854-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2005-12-22 US disclosed
US-6969722-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-11-29 US disclosed
US-20040186128-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-23 US disclosed
EP-1451187-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-01 EP disclosed
US-6720422-B2 MODULATORS OF IMMUNE RESPONSE BY INDUCTION OF CYTOKINE BIOSYNTHESIS; SUBSTITUTED 4-PHENOXY-IMIDAZO(4,5-C)PYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2004-04-13 US disclosed
US-6720333-B2 IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; N-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)BENZAMIDE 3M INNOVATIVE PROPERTIES COMPANY 2004-04-13 US disclosed
US-20030186949-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 US disclosed
US-20030162806-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US disclosed
WO-2003050118-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-6545016-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186128-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG KMT2A 1662/4885MEN1 3701/4885HTT 4679/4885
US-20050282854-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG KMT2A 1662/4885MEN1 3701/4885HTT 4679/4885
US-20030162806-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG KMT2A 1662/4885MEN1 3701/4885HTT 4679/4885
US-20030186949-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG KMT2A 1662/4885MEN1 3701/4885HTT 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.